Bitcoin outperformed the S&P 500 in 50% of U.S. trading sessions over a recent 90-session period ending Nov. 4, marking its first time above this level since March 2025. This session win rate indicates Bitcoin may be regaining strength relative to equities. Historically, when Democrats controlled both the House and Senate during midterms with a Republican president, the S&P 500 saw significant gains in the following months. After Democrats captured both chambers in 2026, U.S. markets rebounded from an initial selloff, though uncertainty remains around the CLARITY Act's impact on the market.
Bitcoin's recent performance versus the S&P 500 is provided here as context. For readers following cryptocurrency markets, Pluang data as of Nov 06, 2026 20:21 WIB shows that among 50 major cryptocurrencies, only 6 rose while 43 fell today. Tezos (XTZ) dropped 6.57% to Rp4.725 with a typical hold time of 101 days, Cosmos (ATOM) fell 6.45% to Rp25.617 with a 40% sell order activity and 61 days hold, and Solana (SOL) declined 5.83% to Rp1.628.420 with a slight majority of sell orders at 52% and 72 days hold time.
BriaCell Therapeutics and its subsidiary BriaPro presented positive preclinical data at the SITC 2026 Annual Meeting, highlighting their immunotherapy platforms Bria-OTS+ and BP-80. Bria-OTS+ showed broad immune activation and sustained cancer cell k...
IMUNON, Inc. presented new data from its Phase 2 OVATION 2 trial showing that IMNN-001, combined with chemotherapy, significantly enhances anti-tumor T-cell immune responses in advanced ovarian cancer patients. This immune activation correlates with ...
Canary Capital has launched the Canary Staked INJ ETF (INJC) on Nasdaq, providing investors exposure to INJ, the native token of the Injective blockchain. The ETF not only tracks INJ's price but also earns staking rewards from the network's proof-of-...
The Ozempic market, valued at $30.04 billion in 2026, is projected to grow to $113.95 billion by 2032, with a CAGR of 24.89%. This growth is fueled by increasing demand for diabetes and metabolic health treatments, wider adoption of GLP-1 therapies, ...
Minerva Neurosciences announced its third quarter 2026 financial results and business updates, highlighting progress in its Phase 3 trial of roluperidone, a drug targeting negative symptoms of schizophrenia. The ongoing C19 study aims to confirm prio...
